nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—ABCC3—Fluorouracil—pancreatic cancer	0.221	0.249	CbGbCtD
Metyrapone—CYP2A6—Tamoxifen—pancreatic cancer	0.133	0.15	CbGbCtD
Metyrapone—ABCC3—Doxorubicin—pancreatic cancer	0.126	0.142	CbGbCtD
Metyrapone—CYP2E1—Dacarbazine—pancreatic cancer	0.11	0.124	CbGbCtD
Metyrapone—CYP2A6—Fluorouracil—pancreatic cancer	0.098	0.111	CbGbCtD
Metyrapone—CYP2E1—Tamoxifen—pancreatic cancer	0.0877	0.099	CbGbCtD
Metyrapone—CYP3A4—Tamoxifen—pancreatic cancer	0.0266	0.03	CbGbCtD
Metyrapone—CYP3A4—Erlotinib—pancreatic cancer	0.0226	0.0255	CbGbCtD
Metyrapone—CYP3A4—Irinotecan—pancreatic cancer	0.0204	0.023	CbGbCtD
Metyrapone—CYP3A4—Docetaxel—pancreatic cancer	0.015	0.0169	CbGbCtD
Metyrapone—CYP3A4—Sunitinib—pancreatic cancer	0.0149	0.0168	CbGbCtD
Metyrapone—Adrenal insufficiency—Sunitinib—pancreatic cancer	0.0112	0.106	CcSEcCtD
Metyrapone—CYP3A4—Doxorubicin—pancreatic cancer	0.0112	0.0126	CbGbCtD
Metyrapone—ABCC3—bile duct—pancreatic cancer	0.00572	0.728	CbGeAlD
Metyrapone—White blood cell count decreased—Sunitinib—pancreatic cancer	0.00473	0.0446	CcSEcCtD
Metyrapone—Hirsutism—Erlotinib—pancreatic cancer	0.00468	0.0441	CcSEcCtD
Metyrapone—Endocrine disorder—Sunitinib—pancreatic cancer	0.00284	0.0268	CcSEcCtD
Metyrapone—Dermatitis atopic—Gemcitabine—pancreatic cancer	0.00255	0.0241	CcSEcCtD
Metyrapone—Dermatitis atopic—Docetaxel—pancreatic cancer	0.00181	0.0171	CcSEcCtD
Metyrapone—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.00165	0.0156	CcSEcCtD
Metyrapone—Pancytopenia—Tamoxifen—pancreatic cancer	0.00164	0.0154	CcSEcCtD
Metyrapone—Abdominal discomfort—Sunitinib—pancreatic cancer	0.00142	0.0134	CcSEcCtD
Metyrapone—Pancytopenia—Sunitinib—pancreatic cancer	0.0014	0.0132	CcSEcCtD
Metyrapone—Bone marrow depression—Epirubicin—pancreatic cancer	0.00134	0.0126	CcSEcCtD
Metyrapone—Bone marrow depression—Doxorubicin—pancreatic cancer	0.00124	0.0117	CcSEcCtD
Metyrapone—Dermatitis atopic—Epirubicin—pancreatic cancer	0.00122	0.0115	CcSEcCtD
Metyrapone—Alopecia—Tamoxifen—pancreatic cancer	0.00122	0.0115	CcSEcCtD
Metyrapone—ABCC3—gall bladder—pancreatic cancer	0.00122	0.155	CbGeAlD
Metyrapone—Alopecia—Erlotinib—pancreatic cancer	0.00121	0.0114	CcSEcCtD
Metyrapone—Dermatitis atopic—Doxorubicin—pancreatic cancer	0.00113	0.0107	CcSEcCtD
Metyrapone—Pancytopenia—Gemcitabine—pancreatic cancer	0.00113	0.0106	CcSEcCtD
Metyrapone—Pancytopenia—Fluorouracil—pancreatic cancer	0.00111	0.0104	CcSEcCtD
Metyrapone—Angiopathy—Sunitinib—pancreatic cancer	0.00107	0.0101	CcSEcCtD
Metyrapone—Alopecia—Sunitinib—pancreatic cancer	0.00105	0.00985	CcSEcCtD
Metyrapone—Hypertension—Tamoxifen—pancreatic cancer	0.00104	0.00978	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00101	0.00948	CcSEcCtD
Metyrapone—Nervous system disorder—Erlotinib—pancreatic cancer	0.000952	0.00897	CcSEcCtD
Metyrapone—Skin disorder—Erlotinib—pancreatic cancer	0.000943	0.00889	CcSEcCtD
Metyrapone—Hypertension—Sunitinib—pancreatic cancer	0.000889	0.00838	CcSEcCtD
Metyrapone—Angiopathy—Irinotecan—pancreatic cancer	0.000884	0.00833	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000871	0.00821	CcSEcCtD
Metyrapone—Angiopathy—Gemcitabine—pancreatic cancer	0.000861	0.00812	CcSEcCtD
Metyrapone—Alopecia—Irinotecan—pancreatic cancer	0.000861	0.00812	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000847	0.00799	CcSEcCtD
Metyrapone—Pain—Tamoxifen—pancreatic cancer	0.000839	0.00791	CcSEcCtD
Metyrapone—Alopecia—Gemcitabine—pancreatic cancer	0.000839	0.00791	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000838	0.0079	CcSEcCtD
Metyrapone—Pain—Erlotinib—pancreatic cancer	0.00083	0.00783	CcSEcCtD
Metyrapone—Alopecia—Fluorouracil—pancreatic cancer	0.000825	0.00777	CcSEcCtD
Metyrapone—Nervous system disorder—Sunitinib—pancreatic cancer	0.000824	0.00777	CcSEcCtD
Metyrapone—Skin disorder—Sunitinib—pancreatic cancer	0.000816	0.00769	CcSEcCtD
Metyrapone—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000802	0.00756	CcSEcCtD
Metyrapone—Pancytopenia—Docetaxel—pancreatic cancer	0.000799	0.00753	CcSEcCtD
Metyrapone—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000794	0.00748	CcSEcCtD
Metyrapone—Abdominal pain—Tamoxifen—pancreatic cancer	0.000776	0.00731	CcSEcCtD
Metyrapone—Abdominal pain—Erlotinib—pancreatic cancer	0.000768	0.00723	CcSEcCtD
Metyrapone—Hypertension—Irinotecan—pancreatic cancer	0.000732	0.0069	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000726	0.00684	CcSEcCtD
Metyrapone—Pain—Sunitinib—pancreatic cancer	0.000719	0.00677	CcSEcCtD
Metyrapone—Hypertension—Gemcitabine—pancreatic cancer	0.000713	0.00672	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000699	0.00658	CcSEcCtD
Metyrapone—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000687	0.00648	CcSEcCtD
Metyrapone—Nervous system disorder—Irinotecan—pancreatic cancer	0.000679	0.0064	CcSEcCtD
Metyrapone—Abdominal pain—Sunitinib—pancreatic cancer	0.000664	0.00626	CcSEcCtD
Metyrapone—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000661	0.00623	CcSEcCtD
Metyrapone—Skin disorder—Gemcitabine—pancreatic cancer	0.000655	0.00617	CcSEcCtD
Metyrapone—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00065	0.00613	CcSEcCtD
Metyrapone—Dizziness—Tamoxifen—pancreatic cancer	0.000649	0.00612	CcSEcCtD
Metyrapone—Hypotension—Irinotecan—pancreatic cancer	0.000647	0.0061	CcSEcCtD
Metyrapone—Dizziness—Erlotinib—pancreatic cancer	0.000642	0.00605	CcSEcCtD
Metyrapone—Hypotension—Gemcitabine—pancreatic cancer	0.00063	0.00594	CcSEcCtD
Metyrapone—Vomiting—Tamoxifen—pancreatic cancer	0.000624	0.00588	CcSEcCtD
Metyrapone—Hypotension—Fluorouracil—pancreatic cancer	0.00062	0.00584	CcSEcCtD
Metyrapone—Vomiting—Erlotinib—pancreatic cancer	0.000617	0.00582	CcSEcCtD
Metyrapone—Headache—Tamoxifen—pancreatic cancer	0.000615	0.00579	CcSEcCtD
Metyrapone—Angiopathy—Docetaxel—pancreatic cancer	0.000611	0.00576	CcSEcCtD
Metyrapone—Headache—Erlotinib—pancreatic cancer	0.000608	0.00573	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000598	0.00563	CcSEcCtD
Metyrapone—Alopecia—Docetaxel—pancreatic cancer	0.000595	0.00561	CcSEcCtD
Metyrapone—Pain—Irinotecan—pancreatic cancer	0.000592	0.00558	CcSEcCtD
Metyrapone—Nausea—Tamoxifen—pancreatic cancer	0.000583	0.00549	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000582	0.00549	CcSEcCtD
Metyrapone—Pain—Gemcitabine—pancreatic cancer	0.000577	0.00544	CcSEcCtD
Metyrapone—Nausea—Erlotinib—pancreatic cancer	0.000577	0.00544	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000572	0.0054	CcSEcCtD
Metyrapone—Pain—Fluorouracil—pancreatic cancer	0.000567	0.00534	CcSEcCtD
Metyrapone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000566	0.00534	CcSEcCtD
Metyrapone—Dizziness—Sunitinib—pancreatic cancer	0.000556	0.00524	CcSEcCtD
Metyrapone—Abdominal pain—Irinotecan—pancreatic cancer	0.000547	0.00516	CcSEcCtD
Metyrapone—Pancytopenia—Epirubicin—pancreatic cancer	0.000539	0.00508	CcSEcCtD
Metyrapone—Vomiting—Sunitinib—pancreatic cancer	0.000534	0.00504	CcSEcCtD
Metyrapone—Headache—Sunitinib—pancreatic cancer	0.000527	0.00496	CcSEcCtD
Metyrapone—Hypertension—Docetaxel—pancreatic cancer	0.000506	0.00477	CcSEcCtD
Metyrapone—Nausea—Sunitinib—pancreatic cancer	0.000499	0.00471	CcSEcCtD
Metyrapone—Pancytopenia—Doxorubicin—pancreatic cancer	0.000499	0.0047	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000496	0.00467	CcSEcCtD
Metyrapone—ABCC3—digestive system—pancreatic cancer	0.00048	0.0611	CbGeAlD
Metyrapone—Nervous system disorder—Docetaxel—pancreatic cancer	0.000469	0.00442	CcSEcCtD
Metyrapone—Skin disorder—Docetaxel—pancreatic cancer	0.000465	0.00438	CcSEcCtD
Metyrapone—Dizziness—Irinotecan—pancreatic cancer	0.000458	0.00432	CcSEcCtD
Metyrapone—Hypotension—Docetaxel—pancreatic cancer	0.000447	0.00422	CcSEcCtD
Metyrapone—Vomiting—Irinotecan—pancreatic cancer	0.00044	0.00415	CcSEcCtD
Metyrapone—Dizziness—Fluorouracil—pancreatic cancer	0.000438	0.00413	CcSEcCtD
Metyrapone—Headache—Irinotecan—pancreatic cancer	0.000434	0.00409	CcSEcCtD
Metyrapone—Vomiting—Gemcitabine—pancreatic cancer	0.000429	0.00404	CcSEcCtD
Metyrapone—Headache—Gemcitabine—pancreatic cancer	0.000422	0.00398	CcSEcCtD
Metyrapone—Vomiting—Fluorouracil—pancreatic cancer	0.000422	0.00397	CcSEcCtD
Metyrapone—Headache—Fluorouracil—pancreatic cancer	0.000415	0.00392	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000413	0.00389	CcSEcCtD
Metyrapone—Angiopathy—Epirubicin—pancreatic cancer	0.000412	0.00389	CcSEcCtD
Metyrapone—Nausea—Irinotecan—pancreatic cancer	0.000411	0.00388	CcSEcCtD
Metyrapone—Pain—Docetaxel—pancreatic cancer	0.000409	0.00386	CcSEcCtD
Metyrapone—Alopecia—Epirubicin—pancreatic cancer	0.000402	0.00378	CcSEcCtD
Metyrapone—Nausea—Gemcitabine—pancreatic cancer	0.000401	0.00378	CcSEcCtD
Metyrapone—Nausea—Fluorouracil—pancreatic cancer	0.000394	0.00371	CcSEcCtD
Metyrapone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000391	0.00369	CcSEcCtD
Metyrapone—Angiopathy—Doxorubicin—pancreatic cancer	0.000381	0.0036	CcSEcCtD
Metyrapone—Abdominal pain—Docetaxel—pancreatic cancer	0.000378	0.00357	CcSEcCtD
Metyrapone—Alopecia—Doxorubicin—pancreatic cancer	0.000372	0.0035	CcSEcCtD
Metyrapone—Hypertension—Epirubicin—pancreatic cancer	0.000341	0.00322	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000334	0.00315	CcSEcCtD
Metyrapone—Nervous system disorder—Epirubicin—pancreatic cancer	0.000317	0.00298	CcSEcCtD
Metyrapone—Dizziness—Docetaxel—pancreatic cancer	0.000316	0.00298	CcSEcCtD
Metyrapone—Hypertension—Doxorubicin—pancreatic cancer	0.000316	0.00298	CcSEcCtD
Metyrapone—Skin disorder—Epirubicin—pancreatic cancer	0.000314	0.00296	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000309	0.00292	CcSEcCtD
Metyrapone—Vomiting—Docetaxel—pancreatic cancer	0.000304	0.00287	CcSEcCtD
Metyrapone—Hypotension—Epirubicin—pancreatic cancer	0.000302	0.00284	CcSEcCtD
Metyrapone—Headache—Docetaxel—pancreatic cancer	0.0003	0.00283	CcSEcCtD
Metyrapone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000293	0.00276	CcSEcCtD
Metyrapone—Skin disorder—Doxorubicin—pancreatic cancer	0.00029	0.00273	CcSEcCtD
Metyrapone—Nausea—Docetaxel—pancreatic cancer	0.000284	0.00268	CcSEcCtD
Metyrapone—Hypotension—Doxorubicin—pancreatic cancer	0.000279	0.00263	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000279	0.00263	CcSEcCtD
Metyrapone—Pain—Epirubicin—pancreatic cancer	0.000276	0.0026	CcSEcCtD
Metyrapone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000264	0.00249	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000258	0.00243	CcSEcCtD
Metyrapone—Pain—Doxorubicin—pancreatic cancer	0.000255	0.00241	CcSEcCtD
Metyrapone—Abdominal pain—Epirubicin—pancreatic cancer	0.000255	0.00241	CcSEcCtD
Metyrapone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000244	0.0023	CcSEcCtD
Metyrapone—CYP2E1—digestive system—pancreatic cancer	0.000242	0.0308	CbGeAlD
Metyrapone—Abdominal pain—Doxorubicin—pancreatic cancer	0.000236	0.00223	CcSEcCtD
Metyrapone—Dizziness—Epirubicin—pancreatic cancer	0.000213	0.00201	CcSEcCtD
Metyrapone—Vomiting—Epirubicin—pancreatic cancer	0.000205	0.00193	CcSEcCtD
Metyrapone—Headache—Epirubicin—pancreatic cancer	0.000202	0.00191	CcSEcCtD
Metyrapone—Dizziness—Doxorubicin—pancreatic cancer	0.000198	0.00186	CcSEcCtD
Metyrapone—CYP3A4—digestive system—pancreatic cancer	0.000195	0.0248	CbGeAlD
Metyrapone—Nausea—Epirubicin—pancreatic cancer	0.000192	0.00181	CcSEcCtD
Metyrapone—Vomiting—Doxorubicin—pancreatic cancer	0.00019	0.00179	CcSEcCtD
Metyrapone—Headache—Doxorubicin—pancreatic cancer	0.000187	0.00176	CcSEcCtD
Metyrapone—Nausea—Doxorubicin—pancreatic cancer	0.000177	0.00167	CcSEcCtD
